Understanding the enzymology of fibrinolysis and improving thrombolytic therapy

Colin Longstaff1, Craig Thelwell

  • 1Division of Haematology, National Institute for Biological Standards and Control, South Mimms, Herts, EN6 3QG, UK. clongstaff@nibsc.ac.uk

FEBS Letters
|June 10, 2005
PubMed

Insights

Understanding clot buster regulation is key to improving treatments for heart attack and stroke. This study uses in vitro methods and computer simulations to better understand plasminogen activation, aiming for enhanced thrombolytic therapy.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Computational Biology

Background:

  • Cardiovascular diseases cause 17 million deaths annually.
  • Thrombolytic drugs, or "clot busters," are plasminogen activators used to treat acute myocardial infarction and stroke.
  • Despite significant investment, clinical trials for new thrombolytic drugs have yielded disappointing results, suggesting incomplete understanding of plasminogen activation regulation in vivo.

Purpose of the Study:

  • To improve the understanding of plasminogen activation regulation in vivo.
  • To facilitate advancements in thrombolytic therapy for cardiovascular diseases.

Main Methods:

  • Development of precise in vitro methods for studying plasminogen activation.
  • Application of computer simulations to analyze and model plasminogen activation pathways.

Main Results:

  • Precise in vitro methods have been established.
  • Computer simulations are being employed to enhance understanding.

Conclusions:

  • Improved understanding of plasminogen activation regulation is crucial for developing more effective thrombolytic therapies.
  • This research aims to bridge the gap between in vitro findings and in vivo mechanisms to improve treatment outcomes for acute myocardial infarction and stroke.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...